Partial response and nonresponse to antidepressant therapy: Current approaches and treatment options

Journal of Clinical Psychiatry

Volumn 63, Issue 9, 2002, Pages 826-837

  Hirschfeld, Robert M A ^a   Montgomery, Stuart A ^a   Aguglia, Eugenio ^a   Amore, Mario ^a   Delgado, Pedro L ^a   Gastpar, Markus ^a   Hawley, Christopher ^a   Kasper, Siegfried ^a   Linden, Michael ^a   Massana, Juan ^a   Mendlewicz, Julien ^a   Möller, Hans Jürgen ^a   Nemeroff, Charles B ^a   Saiz, Jerónimo ^a   Such, Pedro ^a   Torta, Riccardo ^a   Versiani, Marcio ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BUSPIRONE; FLUOXETINE; LITHIUM; MIRTAZAPINE; NEFAZODONE; PINDOLOL; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THYROID HORMONE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CONSTIPATION; DEPRESSION; DIAPHORESIS; DOSE RESPONSE; DRUG ACTIVITY; EVIDENCE BASED MEDICINE; HAMILTON SCALE; HEADACHE; HUMAN; INSOMNIA; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SEROTONINERGIC SYSTEM; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; XEROSTOMIA;

EID: 0036737189     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v63n0913     Document Type: Article

References (113)

1. Hirschfeld RMA, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997;277:333-340
2. Lépine J-P, Gastpar M, Mendlewicz J, DEPRES Steering Committee. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 1997;12:19-29
3. Keller MB, Boland RJ. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol Psychiatry 1998;44:348-360
4. Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 1999;156:1000-1006
5. Holliday SM, Benfield P. Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs 1995;49:280-294
6. Holm KJ, Markham A. Mirtazapine: a review of its use in major depression. Drugs 1999;57:607-631
7. Owens MJ, Morgan WN, Plott SJ, et al. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997;283:1305-1322
8. Holm KJ, Spencer CM. Reboxetine: a review of its use in depression. CNS Drugs 1999;2:65-83
9. Nelson JC. Overcoming treatment resistance in depression. J Clin Psychiatry 1998;59(suppl 16):13-19
10. Fawcett J. Antidepressants: partial response in chronic depression. Br J Psychiatry 1994;165(suppl 26):37-41
11. Fava M, Davidson KG. Definition and epidemiology of treatment resistant depression. Psychiatr Clin North Am 1996;19:179-200
12. Clinical Practice Guideline Number 5: Depression in Primary Care, vol 2. Treatment of Major Depression. Rockville, Md: US Dept Health Human Services, Agency for Health Care Policy and Research; 1993. AHCPR publication 93-0551
13. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999;60:221-225
14. Fava M, Rosenbaum JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994;151:1372-1374
15. Prien RF, Levine J. Research and methodological issues for evaluating the therapeutic effectiveness of antidepressant drugs. Psychopharmacol Bull 1984;20:250-257
16. Montgomery SA, Dufour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry Suppl 1988;9:69-76
17. Souery D, Amsterdam J, de Montigny C, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 1999;9:83-91
18. Ananth J. Treatment-resistant depression. Psychother Psychosom 1998; 67:61-70
19. Burrows GD, Norman TR, Judd FK. Definition and differential diagnosis of treatment-resistant depression. Int Clin Psychopharmacol 1994;9 (suppl 2):5-10
20. Linden M, Helmchen H, Mackert A, et al. Structure and feasibility of a standardized stepwise drug treatment regimen (SSTR) for depressed patients. Pharmacopsychiatry 1994;27:51-53
21. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997;58(suppl 13): 23-29
22. Sharma V, Mazmanian D, Persad E, et al. A comparison of comorbid patterns in treatment-resistant unipolar and bipolar depression. Can J Psychiatry 1995;40:270-274
23. Sharan P, Saxena S. Treatment-resistant depression: clinical significance, concept and management. Natl Med J India 1998;11:69-79
24. Delgado P, Moreno F. Antidepressants and the brain. Int Clin Psychopharmacol 1999;14(suppl 1):S9-S16
25. de Montigny C, Grunberg F, Mayer A, et al. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry 1981;138:252-256
26. de Montigny C, Cournoyer G, Morissette R, et al. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression: correlations with the neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system. Arch Gen Psychiatry 1983;40: 1327-1334
27. Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant treatment: an effective prescription for treatmentrefractory depression. Arch Gen Psychiatry 1983;40:1335-1342
28. Cournoyer G, de Montigny D, Ouellete J, et al. Lithium addition in tricyclic-resistant unipolar depression: a placebo-controlled study [abstract]. Presented at the 14th Congress of the Collegium Internationale Neuro-Psychopharmacologicum (CINP); June 19-23,1984; Florence, Italy
29. Schopf J, Baumann P, Lemarchand T, et al. Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition: results of a placebo-controlled double-blind study. Pharmacopsychiatry 1989;22:183-187
30. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993; 54:269-271
31. Stein G, Bernadt M, Lithium augmentation therapy in tricyclic-resistant depression: a controlled trial using lithium in low and normal doses. Br J Psychiatry 1993;162:634-640
32. Katona CLE, Abou-Saleh MT, Harrison DA, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995;166:80-86
33. Nelson JC. Treatment of antidepressant nonresponders: augmentation or switch? J Clin Psychiatry 1998;59(suppl 15):35-41
34. Joffe RT. Refractory depression: treatment strategies, with particular reference to the thyroid axis. J Psychiatry Neurosci 1997;22:327-331
35. Goodwin FK, Prange AJ Jr, Post RM, et al. Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders. Am J Psychiatry 1982;139:34-38
36. Joffe RT, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res 1990;32:241-251
37. Joffe R, Singer W, Levitt A, et al. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993;50:387-393
38. Thase ME, Howland RH, Friedman ES. Treating antidepressant nonresponders with augmentation strategies: an overview. J Clin Psychiatry 1998;59(suppl 5):5-12
39. Joffe RT, Sokolov ST. Thyroid hormones, the brain, and affective disorders. Crit Rev Neurobiol 1994;8:45-63
40. Gupta S, Masand P, Tanquary JF. Thyroid hormone supplementation of fluoxetine in the treatment of major depression. Br J Psychiatry 1991;159: 866-867
41. 1B/1D receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (±)pindolol. Neuropharmacology 2000;39: 1044-1052
42. Pérez V, Gillaberte I, Faries D, et al. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997;349:1594-1597
43. Tome MB, Isaac MT, Harte R, et al. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997;12:81-89
44. Berman RM, Darnell AM, Miller HL, et al. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 1997;154:37-43
45. Zanardi R, Artigas F, Franchini L, et al. How long should pindolol be associated with paroxetine to improve the antidepressant response? J Clin Psychopharmacol 1997;17:446-450
46. Bordet R, Thomas P, Dupuis B, Réseau de Recherche et d'Expérimentation Psychopharmacologique. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Am J Psychiatry 1998;155: 1346-1351
47. Artigas F, Perez V, Alvarez E. Pindolol induces rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:248-251
48. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 1995;15:217-222
49. Moreno FA, Gelenberg AJ, Bachar K, et al. Pinodolol augmentation in treatment-resistant depressed patients. J Clin Psychiatry 1997;58: 437-439
50. Pérez V, Solaer J, Puigdemont D, et al. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Arch Gen Psychiatry 1999; 56:375-379
51. Rabiner EA, Bhagwagar Z, Gunn RN, et al. Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am J Psychiatry 2001;158:2080-2082
52. Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord 1996;41:201-210
53. Sajatovic M, DiGiovanni S, Fuller M, et al. Nefazodone therapy in patients with treatment-resistant or treatment-intolerant depression and high psychiatric comorbidity. Clin Ther 1999;21:733-740
54. Baron BM, Ogden AM, Siegel BW, et al. Rapid down regulation of beta-adrenoceptors by co-administration of desipramine and fluoxetine. Eur J Pharmacol 1988;154:125-134
55. Nelson JC, Mazure CM, Bowers MB Jr, et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991;48:303-307
56. Nemeroff CB, DeVanc L, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-320
57. Seth R, Jennings AL, Bindman J, et al. Combination treatment with noradrenaline and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 1992;161:562-565
58. Bakish D. Fluoxetine potentiation by buspirone: three case histories. Can J Psychiatry 1991;36:749-750
59. Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 1991;52:217-220
60. Dimitriou EC, Dimitriou CE. Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol 1998;18:465-469
61. Landén M, Björling G, Agren H, et al. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 1998;59: 664-668
62. Appelberg BG, Syvälahti EK, Koskinen TE, et al. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 2001;62: 448-452
63. Harkin A, Kelly JP, Mcnamara M, et al. Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. Eur J Pharmacol 1999;364:123-132
64. Fleishaker JC, Herman BD, Pearson LK, et al. Evaluation of the potential pharmacokinetic/pharmacodynamic interaction between fluoxetine and reboxetine in healthy volunteers. Clin Drug Invest 1999;18:141-150
65. Devarajan S, Dursun SM. The efficacy and safety of reboxetine plus citalopram in treatment-resistant depression: an open, naturalistic case series [abstract]. Presented at the 39th annual meeting of the American College of Neuropsychopharmacology; Dec. 10-14, 2000; San Juan, Puerto Rico
66. Boyer WF, Feighner JP. The combined use of fluoxetine and bupropion. In: New Research Program and Abstracts of the 146th Annual Meeting of the American Psychiatric Association; May 27, 1993; San Fransisco, Calif. Abstract NR746:247
67. Bodkin JA, Kasser RA, Wines JD Jr, et al. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 1997;58:137-145
68. Gerner RH, Kaufman KR, Rosen R. Seizures associated with bupropion and SSRI co-therapy [abstract]. Biol Psychiatry 1998;43(suppl 8):99S
69. Carpenter LL, Jocic Z, Hall JM, et al. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 1999;60:45-49
70. Peselow ED, Filippi AM, Goodnick P, et al. The short- and long-term efficacy of paroxetine HCl, B: data from a double-blind crossover study and from a year-long trial vs imipramine and placebo. Psychopharmacol Bull 1989;25:272-276
71. Montgomery SA. Managing the severely ill and long-term depressed. Int J Psychiatry Clin Pract 1999;3(suppl 1):S13-S17
72. Kasper S. Treatment benefits of reboxetine. Int J Psychiatry Clin Pract 1999;3(suppl 1):S3-S8
73. Mucci M. Reboxetine: a review of antidepressant tolerability. J Psychopharmacol 1997;11(suppl 4):33-37
74. Versiani M, Mehilane L, Gaszner P, et al. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry 1999;60:400-406
75. Paykel E. Social functioning and the depressed patient. Int J Psychiatry Clin Pract 1999;3(suppl 1):S9-S11
76. Dostert P, Benedetti MS, Poggesi I. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol 1997;7(suppl 1):23-35
77. Fava M, McGrath PJ, Sheu W-P, et al. Switching fluoxetine to reboxetine: an efficacy and safety study in depressed patients resistant to fluoxetine [abstract P.03.198]. Int J Neuropsychopharmacol 2000;3(suppl 1):S234
78. Fava M, Dunner DL, Greist JH, et al. An open-label study with mirtazapine in depressed patients who are SSRI treatment failures. In: New Research Program and Abstracts of the 152nd Annual Meeting of the American Psychiatric Association; May 19, 1999; Washington, DC. Abstract NR431:186
79. Spencer CM, Wilde MI. Milnacipran: a review of its use in depression. Drugs 1998;56:405-427
80. Nierenberg AA, Feighner JP, Rudolph R, et al. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14:419-423
81. Saiz-Ruiz J, Ibanez A, Diaz-Marsa M, et al. Response and tolerance to venlafaxine in patients with inefficacy to selective serotonin re-uptake inhibitors [abstract]. Presented at the 21st Congress of the Collegium Internationale Neuro-Psychopharmacologicum (CINP); July 12-16, 1998; Glasgow, Scotland
82. de Montigny C, Silverstone PH, Debonnel G, et al. Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. J Clin Psychopharmacol 1999;19:401-406
83. Fredman SJ, Fava M, Kienke AS, et al. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. J Clin Psychiatry 2000; 61:403-408
84. Mischoulon D, Fava M, Rosenbaum JF. Strategies for augmentation of SSRI treatment: a survey of an academic psychopharmacology practice. Harv Rev Psychiatry 1999;6:322-326
85. The National Institute of Mental Health. Sequenced Treatment Alternatives to Relieve Depression. Available at: http://www.edc.gsph.pitt.edu/stard/index.html-ssi. Accessed Aug 1, 2002
86. Schweitzer I, Tuckwell V. Risk of adverse events with the use of augmentation therapy for the treatment of resistant depression. Drug Saf 1998;19:455-464
87. Reeves RR, Bullen JA. Serotonin syndrome produced by paroxetine and low-dose trazodone. Psychosomatics 1995;36:159-160
88. George TP, Godleski LS. Possible serotonin syndrome with trazodone addition to fluoxetine. Biol Psychiatry 1996;39:384-385
89. John L, Perreault MM, Tao T, et al. Serotonin syndrome associated with nefazodone and paroxetine. Ann Emerg Med 1997;29:287-289
90. Smith DL, Wenegrat BG. A case report of serotonin syndrome associated with combined nefazodone and fluoxetine [letter]. J Clin Psychiatry 2000;61:146
91. Bhatara VS, Magnus RD, Paul KL, et al. Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Ann Pharmacother 1998;32:432-436
92. Muly EC, McDonald W, Steffens D, et al. Serotonin syndrome produced by a combination of fluoxetine and lithium [letter]. Am J Psychiatry 1993;150:1565
93. Lee DO, Lee CD. Serotonin syndrome in a child associated with erythromycin and sertraline. Pharmacotherapy 1999;19:894-896
94. Nemeroff CB, DeVanc L, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-320
95. Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-265
96. Otton SV, Wu D, Joffe RT, et al. Inhibition by fluoxetine of cytochrome P4502D6 activity. Clin Pharmacol Ther 1992;53:401-409
97. Avenoso A, Facciolà G, Scordo NG, et al. No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers. Ther Drug Mon 1999;21:577-579
98. Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 1996;24: 475-490
99. Sproule BA, Naranjo CA, Bremner KE, et al. Selective serotonin reuptake inhibitors and CNS drug interactions: a critical review of the evidence. Clin Pharmacokinet 1997;33:454-471
100. Preskorn SH, Beber JH, Faul JC, et al. Serious adverse effects of combining fluoxetine and tricyclic antidepressants [letter]. Am J Psychiatry 1990;147:532
101. Benazzi F. Anticholinergic toxic syndrome with venlafaxinedesipramine combination. Pharmacopsychiatry 1998;31:36-37
102. Nelson JC. Treatment of refractory depression. Depress Anxiety 1997;5:165-174
103. Crismon ML, Trivedi M, Pigott TA, et al, and the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychiatry 1999;60:142-156
104. Schulberg HC, Katon WJ, Simon GE, et al. Best clinical practice: guidelines for managing major depression in primary medical care. J Clin Psychiatry 1999;60(suppl 7):19-26
105. Quitkin FM, McGrath PJ, Stewart JW, et al. Chronological milestones to guide drug change: when should physicians switch antidepressants? Arch Gen Psychiatry 1996;53:785-792
106. Sackeim HA, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology 2001;25:713-728
107. Goodnick PJ, Rush AJ, George MS, et al. Vagus nerve stimulation in depression. Expert Opin Pharmacother 2001;2:1061-1063
108. Konig F, von Hippel C, Petersdorff T, et al. First experiences in combination therapy using olanzapine with SSRIs (citalopram, paroxetine) in delusional depression. Neuropsychobiology 2001;43:170-174
109. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999;60: 256-259
110. Brown WA, Harrison W. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry 1995; 56:30-34
111. Thase ME, Blomgren SL, Birkett MA, et al. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997;58:16-21
112. Joffe RT, Levitt AJ, Sokolov STH, et al. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry 1996;57:114-115
113. Zarate CA Jr, Kando JC, Tohen M, et al. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J Clin Psychiatry 1996;57:67-71